Automated Breast Ultrasound Systems Market Key Players : GE Electric Co., Siemens A.G., Hitachi Ltd.,SonoCiné Inc., Koninklijke

Rising prevalence of breast cancer across the globe and increasing government initiatives undertaken to encourage breast cancer awareness have significantly fuelled the demand for automated breast ultrasound system, according to ESOMAR-certified Future Market Insights’ (FMI) latest research report. As per the study, the global automated breast ultrasound system market is slated to grow at approximately 10% CAGR over the forthcoming decade.

Key manufacturers are actively focusing on developing faster, accurate and minimal invasive ultrasound breast imaging system. According to report published in National Library of Medicine, integration of mammography with automated breast ultrasound system increased the sensitivity of the system to 99.1%.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-606

The combination drastically improves cancer detection rate among dense breasted women and reduces the interpretation time. Prominent manufacturer GE Healthcare launched a new automated breast ultrasound system named “Invenia” in U.S in October 2018. The main function of the system is to identify the presence of mammographically occult cancer especially in women with dense tissues.

With various other developments on cards, the automated breast ultrasound system market is expected to showcase impressive growth between 2021 and 2031.

“Visibly rising consumer inclination towards radiation free imaging and diagnostics systems is likely to intensify sales of automated breast ultrasound system among diagnostics laboratories,” says the FMI analyst.

Key Takeaways from FMI’s Automated Breast Ultrasound Systems Market Study

  • Increasing government investment to promote breast cancer awareness among women will bolster demand across the U.S.
  • The U.K is expected to experience noteworthy growth as governments and private organizations aim at curbing high mortality rate due to breast cancer.
  • Presence of modern healthcare infrastructure will increase automated breast ultrasound system adoption across Germany
  • Saudi Arabia will offer lucrative opportunities owing to rapid urbanization and emergence of advance diagnostics centers.
  • India is expected to exhibit increasing demand owing to increase in per capita income and to growing incidence of breast cancer among women.
  • Hospitals are expected to lead the market driven by faster accessibility modern tool and availability of skilled professionals.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-606

Competitive Landscape

GE Electric Co., Siemens A.G., Hitachi Ltd., SonoCiné Inc., Koninklijke are some prominent players operating in the automated breast ultrasound system market. They are focusing on improving the accuracy of automated breast ultrasound system for faster assessment of cancer screening in addition to getting government approval for their products.

For instance, Hitachi being the global leader in smart life & eco-friendly systems launched its latest automated breast ultrasound system “SOFIA” capable of scanning and acquiring image of the complete breast.

Koninklijke launched Philips EPIQ and Affiniti ultrasound systems as a part of its automated breast ultrasound system product range. Philips EPIQ is laced with an integrated eL18-4 transducer and employs anatomical intelligence for accurate imaging of the breast with high tissue density.

More Insights on the Global Automated Breast Ultrasound Systems Market

In its latest report, FMI offers an unbiased analysis of the global automated breast ultrasound system market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of end user (hospitals, diagnostic imaging laboratories), across seven major regions (North America, Latin America, Western Europe, Eastern Europe, Japan, Asia Pacific excluding Japan,  and Middle East & Africa)

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-606

Key Segments Covered

By End User

  • Hospitals
  • Diagnostic Imaging Laboratories
  •  America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Western Europe
    • EU-5
    • BENELUX (Belgium, Netherlands, Luxembourg)
    • NORDIC (Denmark, Finland, Iceland, Norway, Sweden)
    • Rest of Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
  • Japan
  • APEJ (Asia Pacific excluding Japan)
    • China
    • India
    • ASEAN Countries
    • Australia & New Zealand
    • Rest of APEJ
  • MEA
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Iran
    • Rest of Middle East & Africa

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Liquid Biopsy Market to expand at a 13.49% value CAGR by 2032 | FMI

[262 Pages Report] As per a recent market survey by ESOMAR-certified consulting firm Future Market Insights (FMI), the global liquid biopsy market is expected to reach a market valuation of US$ 1,026 Mn in 2021.

With the introduction of innovative molecular diagnostic tests and growing demand from biotech and pharmaceutical companies, the market is poised to expand at a stellar 13.49% CAGR, reaching US$ 3,637 Mn by 2031.

Germany, India, and China will emerge as high growth potential markets, with increasing investments by the government for improving the healthcare infrastructure, which will create attractive opportunities to global biotech players for market expansion.

Growth of the liquid biopsy market is attributable to rising incidence of cancer across several countries, which is highlighting the pressing need for faster, simpler, and more convenient diagnostic procedures. Liquid biopsy procedures are minimally invasive and cost-effective, which is making them a favorable choice for cancer diagnosis procedures.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1396

“Increasing incidence of cancer, coupled with incorporation of latest technology in liquid biopsy for faster and more convenient diagnosis will continue to augment the market growth throughout the forecast period,” says the FMI analyst.

Besides this, increasing government-backed initiatives to support cancer research across the U.S., Japan, India and the UK will drive innovation and developments in liquid biopsy services. Also,  fast track approval from regulatory bodies for novel procedures will bolster the growth over the coming years.

Additionally, technological advancements such as the incorporation of machine learning and microchip-based liquid biopsy systems will further strengthen growth prospects in the market.

As per the market survey, counties including the U.S., the U.K, and Japan will be at the forefront of innovation and adoption of liquid biopsy services, owing to the presence of leading players and prevalence of numerous high-potential cancer research institutes.

Key Takeaways from the Liquid Biopsy Market Analysis

  • Based on markers, circular tumor cells (CTC) are poised to emerge dominant in the forthcoming years.
  • Blood samples will emerge as the most preferred sample type
  • In terms of applications, liquid biopsy will be widely preferred for lung cancer diagnosis.
  • Cancer institutes are expected to remain dominant end users, accounting for over 40% of the total revenue share.
  • The U.S. will showcase high growth during the forecast period, due to the presence of major liquid biopsy product manufacturers.
  • The U.K. will emerge as an avenue for product innovations and development, further solidifying growth prospects.
  • Japan is anticipated to witness upswings in sales, owing to government-led cancer research initiatives.
  • India is expected to showcase high demand for liquid biopsy products, owing to the increased funding by government and expansion of healthcare infrastructure.

Competitive Landscape

BIOCEPT, INC., Qiagen N.V., Trovagene, Inc, Janssen Global Services, LLC, MDxHealth SA, Natera, Inc, F. Hoffmann-La Roche Ltd, Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation are among top manufacturers of liquid biopsy products, as profiled by FMI. As per the market survey, tier-1 companies are anticipated to account for approximately 20-25% of the total market share.

Strategic collaborations, partnerships, and product innovations are some of the prominent growth strategies applied by leading market players to establish a strong foothold in the liquid biopsy market. For instance:

  • In June 2021, Biocept Inc., collaborated with Quest Diagnostics, a New Jersey-based clinical laboratory, to offer laboratory services to Quest patients for its Target Selector NGS-based liquid biopsy lung cancer panel.
  • In February 2021, Menarini Silicon Biosystems, a leading developer of liquid biopsy and single-cell technologies, launched its innovative CellMag product line for staining and detection of rare circulating tumor cells (CTCs).

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1396

More Insights into the Liquid Biopsy Market Report

In its latest report, FMI offers an unbiased analysis of the global liquid biopsy market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of marker type (circulating tumor cells (CTC), circulating tumor nucleic acids (cTNA) and exosomes), sample type (blood, urine and other including plasma, saliva and CSF), application type (lung cancer, gastrointestinal cancer, prostate cancer, colorectal cancer, leukemia), end-users (hospitals, cancer institutes, academic institutes, and diagnostic centers) and across seven regions (North America, Latin America, Eastern Europe, Western Europe, Asia Pacific excluding Japan (APEJ), Japan, and Middle East & Africa).

Liquid Biopsy Market by Category

By Marker Type:

  • CTCs (Circulating Tumour Cells)
  • ctNA (Circulating tumor Nucleic Acids)
  • Exosomes

By Sample Type:

  • Blood
  • Urine
  • Others (Plasma, Saliva, CSF)

By Application Type:

  • Lung Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia

By End-Users:

  • Hospitals
  • Cancer Institutes
  • Academic Institutes
  • Diagnostic Centers

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Respiratory Inhaler Devices Market to grow at 4.4% CAGR through 2030 | FMI

Global respiratory inhaler device shipments are likely to grow at over 4% in 2021, as the medical device industry makes a gradual recovery. Innovation in smart inhaler technologies is likely to be a key focus area, but manual inhalers will still account for 90% of total demand. This stark contrast reflects the status-quo in the global medical device industry, where realization of new investment and bottom-lines are concurrent.

[250 Pages Report] The rising prevalence of respiratory disorders has necessitated innovation in manufacture of respiratory inhalers. The demand for better precision in drug delivery is enabling broader adoption of Respiratory Inhaler Devices, especially among patients of asthma and chronic obstructive pulmonary diseases (COPD). Steady growth is expected to continue as favorable reimbursement policies by governments create a conducive environment around the world.

Global demand for respiratory inhaler devices continues to be driven by rising prevalence of COPD and asthma. According to the World Health Organization (WHO), nearly 251 million cases of chronic obstructive pulmonary disease (COPD) were reported worldwide in 2016 and nearly 339 million people were estimated to have asthma in the same year. Coupled with this, surging healthcare spending has been creating lucrative prospects for growth of the market.

Market players also are focusing on novel inhalation technologies to ascertain drug delivery to lungs. Spurred by these factors, the global market for respiratory inhaler devices is expected to report surging sales.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-493

Smart Inhaler Technology Touted as a Major Breakthrough

Smart inhalers have been touted as a disruptive technology, and it remains a key focus area for manufacturers. Smart inhalers can signal patients if their overusing any medication, warning them against poor management of the condition. The technology is touted as a major breakthrough in the healthcare sector and one that is expected to enable growth in the respiratory inhaler devices market in the coming years.

Several studies already are underway gauging the potential of these development. For instance, My AirCoach, which is an EU-funded multi-institutional research project, aims at assessing how novel mobile health technologies, including smart inhalers, can help offering improved asthma control.

With myriad of developments underway, respiratory inhaler device shipments are likely to gain traction through 2030. FMI’s report offers a comprehensive analysis on how growth will unfold. Some of the key takeaways from the report are:

  • Dry powder inhalers remain the most lucrative category
  • Manually operated inhaler devices will remain preferred choice among available technologies
  • Respiratory inhaler devices sales surging to offer improved asthma control and management
  • US to remain a highly lucrative market for respiratory inhaler devices, however, growth in East Asia is expected to accelerate at a higher pace

“Some of the leading players are working on technologies that would enable monitoring and correction of inhalation techniques in the near future. They are developing smart inhalers that will use the Bluetooth technology to monitor inhaler use in patients. While several developments are underway, industry experts are cautiously examining the potential of smart inhalers to ensure all potential concerns pertaining to the novel technologies are ironed out. However once launched, smart technology can help the market gain momentum at accelerated pace in the near future,” said a lead analyst at FMI.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-493

Some of the leading companies are focusing on innovations and product launches to gain competitive advantage. There also are companies trying to capitalize on opportunities across high potential markets. For instance, Zydus Cadila has announced launching India’s first pressurized Metered Dose Inhaler (pMDI) – Forglyn pMDI with a combination of Long Acting Beta Agonist (LABA) and Long Acting Muscarinic Antagonist (LAMA) for COPD patients in October 2020.

In 2019, Lupin announced launching “ADHERO,” which is a connected smart device for metered dose inhalers and promises to ensure improved adherence to inhalation therapy for COPD treatment.

In the latest report by Future Market Insights, we offer an unbiased analysis of the global respiratory inhaler devices market, providing historical data for the period of 2015-2019 and forecast statistics for the period of 2020-2030. In order to understand the global market potential, its growth and scopes, the market is segmented on the basis of product type (dry powder inhaler, metered dose inhaler, and nebulizer), technology (manually operated inhaler devices and digitally operated inhaler devices), disease indication (asthma, COPD, pulmonary arterial hypertension, other respiratory diseases), across six major regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA).

Key Segments

Product

  • Dry Powder Inhalers
  •  Metered Dose Inhalers
  • Nebulizers
    • Compressed Air Nebulizers
    • Ultrasonic Nebulizers
    • Mesh Nebulizers

Technology

  • Manually Operated Inhaler Devices
  • Digitally Operated Inhaler Devices

Disease Indication

  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Pulmonary Arterial Hypertension
  • Others

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/493

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Middle East and Africa (MEA)
  • Oceania

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Herbal Medicinal Products Market is estimated to reach US$ 360.35 Billion by the end of 2031

Government initiatives undertaken around the world, especially in the West to encourage the use of herbal medicine has resulted in the development of mass distribution networks, increasing prescription of homeopathic medications, and demand for Ayurveda treatments.

According to a recent study by Future Market Insights (FMI), these factors have proven crucial at enabling growth in the herbal medicinal market. Sales of herbal medicines are expected to top US$ 171.62 Bn in 2021, at a CAGR of 7.7% during the forecast period (2021-2031).

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2722

Soaring concerns pertaining to adverse effects of allopathic medicines has been causing gradual shift of preference in favor of traditional herbal medicines. These medicines are often used for treatment of ailments including neurological diseases, cough, cold & flu, sexual problems, feminine problems, and metabolic diseases. Herbal remedies are used to maintain health and systemic balance, of body functions without sedation and side effects.

In 2015, La Political de Attention Integral a la Saluda Indigene de FUNASA of Brazil promoted traditional systems of health of indigenous communities. Similarly, the government has recognized homeopathic medicines as a medical specialty and included it in the National Health System. Brazil is currently home to around 12,000 homeopathic physicians and 300 homeopathic pharmacists.

As per the World Health Organization (WHO), around 60% of the world’s population is reliant on herbal medicines for primary health care needs. In developing countries, this number accounts for up to 80%. Around 75% of such sales are made through direct user-pharmacy contacts. The growing trend of online pharmacies and mail-on-order purchases drives the demand for self-medication.

The global geriatric population is rapidly expanding with higher life expectancy rates. According to the World Bank, in 1990, the average mortality among geriatric world population was around 6 %, which increased to 9.5% in 2020. The prevalence of chronic diseases associated with an aging population portrays the need for effective medications.

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-2722

Key Takeaways from Protein A Resin Study:

  • Demand for Chinese medicines is expected to grow at 8.2% CAGR through 2031, owing to investments into promotion of traditional Chinese medicine.
  • Retail pharmacies are projected to capture over 23% of the global market by 2031. This is attributed to availability of consumer health products.
  • Europe is the largest revenue-generating region for herbal medicinal products, with Germany accounting for nearly 18% of the regional market in 2031.
  • China holds the leading position in East Asia, and is expected to account for over 49% of the market in 2031.
  • South Asia is the third most lucrative market with India accounting for over 74% of the share in 2031.

Competitive Landscape

  • Manufacturers of herbal medicine are primarily aiming to carry out strategic expansions and filing patents to consolidate growth in a competitive market.
  • For Instance, In Oct 2020, the Arkopharma SA filled a patent for the Arkodigest® No Reflux 100% natural composition to improve digestion.
  • In November 2020, Mountain Rose Herbs purchased the Phoenix Industrial Park in Eugene, with 205,000 square feet of operational space and a 12-acre campus, as a part of business expansion strategy to develop it into green space.

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-2722

The key market players covered by FMI include :

  • Blackmores Limited,
  • Sanofi-Aventis Healthcare PTY Ltd.,
  • Arkopharma SA,
  • Nutraceutical Corporation,
  • STADA Arzneimittel AG,
  • Himalaya Global Holdings Ltd,
  • Integria Healthcare,
  • Boiron Group,
  • Young Living Essential Oils,
  • Mountain Rose Herbs

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Safety Needles Market valuation in excess of US$ 2,500 Million by 2027 | Exclusive Report by FMI

[277 Pages Report] The global safety needles market was worth $5,123 million in 2021 and is expected to grow at a 7.6% CAGR during the forecast period (2022-2032). In terms of end users, hospital pharmacies are expected to lead the global safety needles market by 2021, with a total valuation of approximately US$ 2.6 billion. By the end of 2032, the global market is expected to be worth US$ 11,370 Mn.

Rising Focus on Use of Prefilled Syringes Fuelling the Demand

At present, value of the global safety needles market is estimated to be s worth US$ 3,752.2 Mn, and it is estimated to reach US$ 7,765.7 Mn by 2027-end, witnessing a CAGR of 6.9% during this forecast period. The growing focus on utilization of prefilled syringes for treatment of several ailments is fuelling the demand for safety needles across the globe. Factors such as changing lifestyle habits, exposure to hormones and infection by HCV are expected to result in gynaecological cancers. Rising incidence rate of gynaecological cancers, coupled with higher presence of lower-back problems in regions such as the US are driving the demand for spine needles and other types of safety needles.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-2029

Safety Needles Market

The sole purpose of designing safety needles was to avoid needlestick injuries while collecting fluids and delivering drugs to the body. The key players of global market for safety needles are enhancing their product portfolio by focusing on production of innovative needles with safety features. These players include B. Braun Melsungen AG, Novo Nordisk A/S, Medtronic, and Becton, Dickinson and Company. Becton, Dickinson and Company holds its dominance in the overall market with around 50% share, followed by Medtronic and Novo Nordisk AS. Future Market Insights’ recent report profiles Smith Medical and Argon medical Inc. as emerging safety needle manufacturers, while Terumo Medical Corporation and Boston Scientific Inc. are recognised as mid-level players in the global safety needles market.

Trends Observed in the Global Safety Needles Market

Leading companies are participating in campaigns in co-ordination with governments of several economies for raising awareness about unsafe use of reusable needles among patients. Increasing prevalence of HIV & blood-borne diseases, owing to needle injuries, has also urged the companies for development of needles with enhanced safety features.

Key findings from FMI’s Report Include

  • Hypodermic needles, as a product, will dominate the market, and is expected to account for 18.1% share during the forecast period. However, biopsy needles are expected to witness fastest revenue growth at 8.6% CAGR.
  • Hospital pharmacies are estimated to account for more than half of safety needles being distributed globally, while private clinics are expected to garner over US$ 1,300 Mn through 2027.
  • Drug delivery application of safety needles is expected to gain 242 BPS in its market share. In addition, sample collection is projected to create an absolute $ opportunity of around US$ 1,840 Mn in 2017 over 2016.

APEJ – Fastest-Growing Safety Needles Market in World

Around 24% market share is estimated to be held by Western Europe by the end of 2027, while APEJ is expected to register fastest growth in the global market for safety needles. In contrast, Eastern Europe is poised to depict a sluggish growth during the forecast period, while North America is will remain the outright dominant region in the global market for safety needles.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-2029

Market segmentationProduct Type

  • Fine Aspirating Needles
  • Biopsy Needles
  • Hypodermic Needles
  • Pen Needles
  • Suture Needles
  • IV Catheter Needles
  • Blood Collection Needles
  • Spinal Anesthesia and Epidural Needles
  • Prefilled Needles
  • A.V. Fistula Needles
  • Cannula Needles
  • Huber Needles

Application

  • Sample Collection
  • Drug Delivery

Distribution Channel

  • Hospital Pharmacies
  • Private Clinics
  • Retail Pharmacies and Drug Stores
  • E-Commerce

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Auto-Injectors Market is projected to enjoy a valuation of US$ 3.5 Bn in 2022, Says FMI

[276 Pages Report] The global auto-injectors market is expected to be worth US$ 3.5 billion in 2022, and to grow at an impressive CAGR of 21.4% between 2022 and 2032, to be worth US$ 23.9 billion in 2032. Rising prevalence of diseases such as diabetes, anaphylaxis, and multiple sclerosis, as well as an increase in drug self-administration, are some of the key factors driving market demand for auto-injectors.

Anaphylactic shock is the most common chronic disease in Europe and North America region. Allergy UK says, approximately 20% of patients struggle with anaphylactic reaction in Europe. Anaphylactic shock requires adrenaline auto injector devices to be treated. Adrenaline auto injectors are sold under various brands, such as Emerade, Epipen and Jext in the UK. The global auto injectors market was valued at US$ US$ 1,700 Mn, in terms of value, in 2016, according to the latest research by Future Market Insights (FMI). The report on auto injectors further projects significant growth potential with average year-on-year growth rate of 15.1% through 2026.

Auto injectors are an effective mode of administration for intramuscular drugs. User friendly attributes of auto injectors reduce the burden of carrying conventional needles and syringes. However, limited awareness regarding proper use of auto injectors and high price of branded products are some of the important factors curbing the adoption of auto injector devices in emergency applications.

Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1642

Based on research conducted by the McGill University’s Health Centre Research Institute, allergic patients procuring EpiPen for emergency are not actually using the product as quickly as they should. Further, a number of patients visiting the emergency department due to severe anaphylaxis reaction are already administered epinephrine, says the Journal of Allergy and Clinical Immunology.

Failure to use auto injectors at the right time is mainly due to lack of knowledge about signs of anaphylaxis. Such lack of awareness about the disease and product creates significant challenges, in terms of product adoption, for the manufacturers. Apart from higher pricing, limited shelf life of auto-injector pen & under supply of products (Ex. EpiPen) are the major challenges hindering the patient preference for auto injectors in emergency.

Increasing innovations in materials and device functions of auto-injectors are driving the expansion of the auto injector market. In September 2015, Bayer HealthCare reported the launch of Betaconnect- an electronic auto injector for the treatment of relapsing-remitting multiple sclerosis (RRMS). This auto injector offers complete drug dosage for improved compliance and potentially reduce the overall cost. The SHL Group offers a variety of auto injectors that can accommodate changes in injections, such as larger volumes, high viscosity and others. The auto-injector manufacturers are focusing on improving the functionality of auto-injectors to improve disease management and treatment.

Fierce competition in the auto injectors market due to the patient protection act has created an oligopolistic market environment. As a result, brands, such as EpiPen auto-injector, BD Physioject disposable auto injector, etc., have maintained their ranks in the market. However, recent patient expiration and increasing pressure from government bodies will led to reduction in auto injector prices and thus, reduce the profitability for branded manufacturers.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1642

Generic auto injectors are expected to present high growth opportunities for investors due to growing support from private insurance providers. Insurance services providers are dropping coverage on highly priced auto injectors and covering newly launched half priced generics. Overall revenue from pre-filled syringes is expected to grow during the forecast period due to rising need for targeted and sustained drug delivery. New entrants must comprehensively study the Auto Injectors market to penetrate and sustain in the price sensitive market. The study of the market scenario will provide insights about the business opportunities

FMI has segmented the global auto injector market by product type, indication, distribution channel & regions. In terms of revenues, pre-filled auto injectors will hold substantial market share over the forecast period. On the contrary, the Fillable auto-injectors segment will exhibit limited investment opportunities, in terms of revenue, through 2026.

This FMI report covers some of the key companies operating in the auto injectors market, such as

  • Sanofi, Pfizer, Inc.,
  • Becton,
  • Dickinson and Company,
  • Mylan N.V.,
  • Novartis AG,
  • Janssen Global Services,
  • LLC,
  • Antares Pharma,
  • Amgen Inc.
  • Bayer AG, & Eli Lilly and Company.

Buy Complete Report@ https://www.futuremarketinsights.com/checkout/1642

Key Segment

based on product type

  • Prefilled Auto-injectors
  • Fillable auto-injectors

based on distribution channel

  • Traditional sales channels
  • hospital pharmacies
  • retail pharmacies

based on regions

  • North America
  • Latin America
  • Europe
  • Asia Pacific Excluding Japan
  • Japan
  • MEA

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Veterinary Vaccines Market is forecast to grow at a healthy CAGR of 7.2% between 2022 and 2026, surpassing a valuation of around US$ 14.1 Bn by 2026

[193 Pages Report] Immunization and vaccination are accepted as the most cost-effective and viable method of controlling infectious veterinary diseases. Veterinary vaccines play an important role in the reduction of diseases, in both, livestock and companion animals.

Increasing awareness regarding animal health and growing demand for animal protein food products are key factors expected to augur well for the veterinary vaccines market. Veterinary vaccines are witnessing demand upsurge, globally, owing to increasing government-backed initiatives for the prevention of zoonotic diseases.

The global veterinary vaccines market is projected to be valued at US$ 9.1 Bn in 2022, and is expected to witness a CAGR of nearly 7% during the forecast period (2022–2026).

However, the coronavirus (COVID-19) pandemic has exposed the market to several uncertainties. With initial speculations blaming meat products for the transmission, the veterinary vaccines market witnessed a slowdown. That being said, further investigations have revealed that, meat consumption is not responsible for the COVID-19 contagion. As such, the veterinary vaccines market is gradually coming back on track, backed by increasing demand for animal-based products such as eggs, milk, and meat.

“Development of new and effective veterinary vaccines such as recombinant vaccines for infectious, parasitic, and metabolic diseases, and increasing animal disease eradication programs, will boost the growth of the veterinary vaccines market over the coming years.”

Key Takeaways of Veterinary Vaccines Market Study

  • Attenuated live vaccines emerged as the largest segment by product, representing around 24% revenue share in veterinary vaccines market in 2021. Attenuated live vaccines are effective and are widely preferred for the treatment of animal diseases; they are expected to exhibit significant growth over the forecast period.
  • By disease, the foot & mouth disease accounted for the highest revenue in 2021. High prevalence of foot & mouth disease is anticipated to drive demand for veterinary vaccines, worldwide.
  • Veterinary clinics hold over 2/5 share of the veterinary vaccines market value, owing to increasing number of veterinary clinics.
  • Based on species, livestock animals account for a leading revenue share in the veterinary vaccines market, owing to higher demand for livestock vaccines for better quality of meat and processed meat export.
  • Cumulatively, North America and Western Europe contribute over 58% share in the global veterinary vaccines market, with North America leading the pack in terms of revenue share.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-409

Acquisition a Prominent Strategy Adopted by Veterinary Vaccine Manufacturers

The acquisition strategy helps in complementing the vaccine portfolio that adds significant value to an organization. For instance, in June 2016, Boehringer Ingelheim International GmbH signed an agreement with Sanofi’s animal-health business (Merial). In July 2018, Zoetis acquired Nexvet Biopharma. This collaboration strengthened the development platform of mAb therapies and added new alternatives to treat osteoarthritis in companion animals.

Want more insights?

Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. The global veterinary vaccines market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights on the veterinary vaccines market on the basis of product (attenuated live vaccines, conjugate vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, and recombinant vaccines), disease (anaplasmosis, canine parvovirus, foot & mouth disease, new castle disease, distemper disease, influenza, porcine reproductive & respiratory syndrome (PRRS), and others), distribution channel (veterinary clinics, veterinary hospitals, veterinary research institutes, and retail pharmacies), and species (companion animals, companion animals, and equine), across seven major regions.

Key Segments of Veterinary Vaccines Industry Survey

By Product:

  • Attenuated Live Vaccines
  • Conjugate Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • DNA Vaccines
  • Recombinant Vaccines

By Disease:

  • Anaplasmosis
  • Canine Parvovirus
  • Foot & Mouth Disease
  • New Castle Disease
  • Distemper Disease
  • Influenza
  • Porcine Reproductive & Respiratory Syndrome (PRRS)
  • Others

By Distribution Channel:

  • Veterinary Clinics
  • Veterinary Hospitals
  • Veterinary Research Institutes
  • Retail Pharmacies

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-409

By Species:

  • Companion Animals
    • Canine
    • Avian
    • Feline
  • Livestock Animals
    • Aquatic
    • Bovine
    • Porcine
    • Ovine/Caprine
    • Poultry
  • Equine

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Respiratory Inhaler Devices Market to grow at 4.4% CAGR through 2030, Says Future Market Insights

[250 Pages Report] Global respiratory inhaler device shipments are likely to grow at over 4% in 2021, as the medical device industry makes a gradual recovery. Innovation in smart inhaler technologies is likely to be a key focus area, but manual inhalers will still account for 90% of total demand. This stark contrast reflects the status-quo in the global medical device industry, where realization of new investment and bottom-lines are concurrent.

The rising prevalence of respiratory disorders has necessitated innovation in manufacture of respiratory inhalers. The demand for better precision in drug delivery is enabling broader adoption of Respiratory Inhaler Devices, especially among patients of asthma and chronic obstructive pulmonary diseases (COPD). Steady growth is expected to continue as favorable reimbursement policies by governments create a conducive environment around the world.

Global demand for respiratory inhaler devices continues to be driven by rising prevalence of COPD and asthma. According to the World Health Organization (WHO), nearly 251 million cases of chronic obstructive pulmonary disease (COPD) were reported worldwide in 2016 and nearly 339 million people were estimated to have asthma in the same year. Coupled with this, surging healthcare spending has been creating lucrative prospects for growth of the market.

Market players also are focusing on novel inhalation technologies to ascertain drug delivery to lungs. Spurred by these factors, the global market for respiratory inhaler devices is expected to report surging sales.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-493

Smart Inhaler Technology Touted as a Major Breakthrough

Smart inhalers have been touted as a disruptive technology, and it remains a key focus area for manufacturers. Smart inhalers can signal patients if their overusing any medication, warning them against poor management of the condition. The technology is touted as a major breakthrough in the healthcare sector and one that is expected to enable growth in the respiratory inhaler devices market in the coming years.

Several studies already are underway gauging the potential of these development. For instance, My AirCoach, which is an EU-funded multi-institutional research project, aims at assessing how novel mobile health technologies, including smart inhalers, can help offering improved asthma control.

With myriad of developments underway, respiratory inhaler device shipments are likely to gain traction through 2030. FMI’s report offers a comprehensive analysis on how growth will unfold. Some of the key takeaways from the report are:

  • Dry powder inhalers remain the most lucrative category
  • Manually operated inhaler devices will remain preferred choice among available technologies
  • Respiratory inhaler devices sales surging to offer improved asthma control and management
  • US to remain a highly lucrative market for respiratory inhaler devices, however, growth in East Asia is expected to accelerate at a higher pace

“Some of the leading players are working on technologies that would enable monitoring and correction of inhalation techniques in the near future. They are developing smart inhalers that will use the Bluetooth technology to monitor inhaler use in patients. While several developments are underway, industry experts are cautiously examining the potential of smart inhalers to ensure all potential concerns pertaining to the novel technologies are ironed out. However once launched, smart technology can help the market gain momentum at accelerated pace in the near future,” said a lead analyst at FMI.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-493

Some of the leading companies are focusing on innovations and product launches to gain competitive advantage. There also are companies trying to capitalize on opportunities across high potential markets. For instance, Zydus Cadila has announced launching India’s first pressurized Metered Dose Inhaler (pMDI) – Forglyn pMDI with a combination of Long Acting Beta Agonist (LABA) and Long Acting Muscarinic Antagonist (LAMA) for COPD patients in October 2020.

In 2019, Lupin announced launching “ADHERO,” which is a connected smart device for metered dose inhalers and promises to ensure improved adherence to inhalation therapy for COPD treatment.

In the latest report by Future Market Insights, we offer an unbiased analysis of the global respiratory inhaler devices market, providing historical data for the period of 2015-2019 and forecast statistics for the period of 2020-2030. In order to understand the global market potential, its growth and scopes, the market is segmented on the basis of product type (dry powder inhaler, metered dose inhaler, and nebulizer), technology (manually operated inhaler devices and digitally operated inhaler devices), disease indication (asthma, COPD, pulmonary arterial hypertension, other respiratory diseases), across six major regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA).

Key Segments

Product

  • Dry Powder Inhalers
  •  Metered Dose Inhalers
  • Nebulizers
    • Compressed Air Nebulizers
    • Ultrasonic Nebulizers
    • Mesh Nebulizers

Technology

  • Manually Operated Inhaler Devices
  • Digitally Operated Inhaler Devices

Disease Indication

  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Pulmonary Arterial Hypertension
  • Others

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/493

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Middle East and Africa (MEA)
  • Oceania

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Automated Breast Ultrasound Systems Market Top Trends and industry overview to watch for in 2031

Rising prevalence of breast cancer across the globe and increasing government initiatives undertaken to encourage breast cancer awareness have significantly fuelled the demand for automated breast ultrasound system, according to ESOMAR-certified Future Market Insights’ (FMI) latest research report. As per the study, the global automated breast ultrasound system market is slated to grow at approximately 10% CAGR over the forthcoming decade.

Key manufacturers are actively focusing on developing faster, accurate and minimal invasive ultrasound breast imaging system. According to report published in National Library of Medicine, integration of mammography with automated breast ultrasound system increased the sensitivity of the system to 99.1%.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-606

The combination drastically improves cancer detection rate among dense breasted women and reduces the interpretation time. Prominent manufacturer GE Healthcare launched a new automated breast ultrasound system named “Invenia” in U.S in October 2018. The main function of the system is to identify the presence of mammographically occult cancer especially in women with dense tissues.

With various other developments on cards, the automated breast ultrasound system market is expected to showcase impressive growth between 2021 and 2031.

“Visibly rising consumer inclination towards radiation free imaging and diagnostics systems is likely to intensify sales of automated breast ultrasound system among diagnostics laboratories,” says the FMI analyst.

Key Takeaways from FMI’s Automated Breast Ultrasound Systems Market Study

  • Increasing government investment to promote breast cancer awareness among women will bolster demand across the U.S.
  • The U.K is expected to experience noteworthy growth as governments and private organizations aim at curbing high mortality rate due to breast cancer.
  • Presence of modern healthcare infrastructure will increase automated breast ultrasound system adoption across Germany
  • Saudi Arabia will offer lucrative opportunities owing to rapid urbanization and emergence of advance diagnostics centers.
  • India is expected to exhibit increasing demand owing to increase in per capita income and to growing incidence of breast cancer among women.
  • Hospitals are expected to lead the market driven by faster accessibility modern tool and availability of skilled professionals.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-606

Competitive Landscape

GE Electric Co., Siemens A.G., Hitachi Ltd., SonoCiné Inc., Koninklijke are some prominent players operating in the automated breast ultrasound system market. They are focusing on improving the accuracy of automated breast ultrasound system for faster assessment of cancer screening in addition to getting government approval for their products.

For instance, Hitachi being the global leader in smart life & eco-friendly systems launched its latest automated breast ultrasound system “SOFIA” capable of scanning and acquiring image of the complete breast.

Koninklijke launched Philips EPIQ and Affiniti ultrasound systems as a part of its automated breast ultrasound system product range. Philips EPIQ is laced with an integrated eL18-4 transducer and employs anatomical intelligence for accurate imaging of the breast with high tissue density.

More Insights on the Global Automated Breast Ultrasound Systems Market

In its latest report, FMI offers an unbiased analysis of the global automated breast ultrasound system market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of end user (hospitals, diagnostic imaging laboratories), across seven major regions (North America, Latin America, Western Europe, Eastern Europe, Japan, Asia Pacific excluding Japan,  and Middle East & Africa)

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-606

Key Segments Covered

By End User

  • Hospitals
  • Diagnostic Imaging Laboratories
  •  America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Western Europe
    • EU-5
    • BENELUX (Belgium, Netherlands, Luxembourg)
    • NORDIC (Denmark, Finland, Iceland, Norway, Sweden)
    • Rest of Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
  • Japan
  • APEJ (Asia Pacific excluding Japan)
    • China
    • India
    • ASEAN Countries
    • Australia & New Zealand
    • Rest of APEJ
  • MEA
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Iran
    • Rest of Middle East & Africa

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

HIV Diagnostics Market is projected to rise from US$ 3.0 Billion in 2022

As per Future Market Insights, the HIV diagnostics market is predicted to rise from US$ 3.0 Bn in 2022 to US$ 6.4 Bn in 2032. The HIV diagnostics market is anticipated to record a steady CAGR of 7.9% during the period 2022-2032.

Technological improvements and increasing prevalence of HIV in developing and underdeveloped countries will foster the industry growth. HIV is one of the serious public health challenges across the globe. HIV if not treated on time can lead to formation of AIDS.

Despite numerous research and advances in scientific studies related to HIV still there is no vaccine and preventive medication to control the spread of the infection. One of the only methods to tackle the infectious is by treating it on time and access to proper treatment and care.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14678

Therefore, many governments, NGO’s and other organizations play a crucial role in creating proper awareness for the prevention of HIV/AIDS. Governments across the globe are undertaking numerous initiatives to educate its citizens regarding prevention and safer sex practices. They are developing better healthcare infrastructure to provide sophisticated patient care as well as management.

“Favourable regulatory environment and substantial investment in R&D activities by market participants for the development of improved quality HIV testing kits for home use is likely to propel the HIV diagnostics market growth.”

The demand for HIV diagnostics is forecasted to grow due to factors such as the rising global prevalence of HIV/AIDS, as well as the rising number of blood transfusions and blood donations.

What is the Segmentation Outlook for the HIV Diagnostics Market?

The consumable sector accounted for the largest market share in the global HIV diagnosis market. Consumption of consumables such as assays, reagents, and kits are on the rise, which is propelling the HIV diagnostics market forward.

HIV Diagnostics Market Key Players

  • Siemens Healthineers
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo-Fisher Scientific Inc

Report Customization available @ https://www.futuremarketinsights.com/customization-available/rep-gb-14678

HIV Diagnostics Market Key Segments

By Product:

  • Consumables
  • Instruments
  • Software & Services

By Test Type:

  • Antibody Tests
  • Viral Load Tests
  • CD4 Tests
  • Others

By End User:

  • Diagnostic Laboratories
  • Hospitals
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Ask an Analyst @ https://www.futuremarketinsights.com/askus/rep-gb-14678

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Summary of Statistics

    1.3. Key Market Characteristics & Attributes

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

    3.1. Risk Assessment

        3.1.1. COVID-19 Crisis and Impact on HIV Diagnostics

        3.1.2. COVID-19 Impact Benchmark with Previous Crisis

        3.1.3. Impact on Market Value (US$ Mn)

        3.1.4. Assessment by Key Countries

        3.1.5. Assessment by Key Market Segments

        3.1.6. Action Points and Recommendation for Suppliers

    3.2. Key Trends Impacting the Market

    3.3. Formulation and Product Development Trends

4. Market Background

    4.1. HIV Diagnostics Market, by Key Countries

    4.2. HIV Diagnostics Market Opportunity Assessment (US$ Mn)

        4.2.1. Total Available Market

        4.2.2. Serviceable Addressable Market

        4.2.3. Serviceable Obtainable Market

    4.3. Market Scenario Forecast

        4.3.1. Demand in optimistic Scenario

        4.3.2. Demand in Likely Scenario

        4.3.3. Demand in Conservative Scenario

    4.4. Investment Feasibility Analysis

        4.4.1. Investment in Established Markets

            4.4.1.1. In Short Term

            4.4.1.2. In Long Term

        4.4.2. Investment in Emerging Markets

            4.4.2.1. In Short Term

            4.4.2.2. In Long Term

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs